GlassScriptPhysician profile
Jose L Milera
NPI 1144689639
$1,667.87
in general payments reported to CMS, 2019-2025
18 companies · $596 in 2025
The $596 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $444 · 2024: $627 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.65 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $454.81 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $320.46 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $142.25 | 2023-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $132.35 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.70 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.75 | 2023-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $80.35 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $70.20 | 2023-2024 | Xarelto |
| Abbott Laboratories | $43.58 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $32.30 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $27.71 | 2024 | Immunocap |
| Abbvie INC. | $27.48 | 2023 | |
| Mannkind Corporation | $24.90 | 2023 | Afrezza |
| Dexcom, INC. | $24.43 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $22.45 | 2025 | Gemtesa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22.08 | 2023 | Uzedy |
| Glaxosmithkline, LLC. | $21.42 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $14.65 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Milera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.